vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and PCB BANCORP (PCB). Click either name above to swap in a different company.
PCB BANCORP is the larger business by last-quarter revenue ($29.2M vs $18.7M, roughly 1.6× CytomX Therapeutics, Inc.). On growth, PCB BANCORP posted the faster year-over-year revenue change (11.3% vs -25.7%). PCB BANCORP produced more free cash flow last quarter ($24.4M vs $-15.8M). Over the past eight quarters, PCB BANCORP's revenue compounded faster (10.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
CTMX vs PCB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $29.2M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 45.0% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | 11.3% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $29.2M | ||
| Q3 25 | — | $30.4M | ||
| Q2 25 | $18.7M | $29.3M | ||
| Q1 25 | $50.9M | $26.9M | ||
| Q4 24 | $38.1M | $26.2M | ||
| Q3 24 | $33.4M | $25.3M | ||
| Q2 24 | $25.1M | $24.2M | ||
| Q1 24 | $41.5M | $23.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | $11.4M | ||
| Q2 25 | $-154.0K | $9.1M | ||
| Q1 25 | $23.5M | $7.7M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $7.8M | ||
| Q2 24 | $-6.5M | $6.3M | ||
| Q1 24 | $13.8M | $4.7M |
| Q4 25 | — | 45.0% | ||
| Q3 25 | — | 52.3% | ||
| Q2 25 | -6.9% | 43.3% | ||
| Q1 25 | 44.4% | 40.2% | ||
| Q4 24 | 46.4% | 39.3% | ||
| Q3 24 | 12.3% | 42.2% | ||
| Q2 24 | -33.7% | 36.3% | ||
| Q1 24 | 28.1% | 27.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 37.5% | ||
| Q2 25 | -0.8% | 31.0% | ||
| Q1 25 | 46.2% | 28.8% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 30.8% | ||
| Q2 24 | -26.0% | 25.9% | ||
| Q1 24 | 33.3% | 19.6% |
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.78 | ||
| Q2 25 | — | $0.62 | ||
| Q1 25 | — | $0.53 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $0.52 | ||
| Q2 24 | — | $0.43 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $207.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $390.0M |
| Total Assets | $175.1M | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $207.1M | ||
| Q3 25 | — | $369.5M | ||
| Q2 25 | $49.0M | $263.6M | ||
| Q1 25 | $47.6M | $214.3M | ||
| Q4 24 | $38.1M | $198.8M | ||
| Q3 24 | $40.6M | $193.1M | ||
| Q2 24 | $43.2M | $177.6M | ||
| Q1 24 | $36.2M | $239.8M |
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $384.5M | ||
| Q2 25 | $119.9M | $376.5M | ||
| Q1 25 | $25.0M | $370.9M | ||
| Q4 24 | $-456.0K | $363.8M | ||
| Q3 24 | $-23.5M | $362.3M | ||
| Q2 24 | $-31.2M | $353.5M | ||
| Q1 24 | $-31.7M | $350.0M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | $175.1M | $3.3B | ||
| Q1 25 | $98.5M | $3.2B | ||
| Q4 24 | $120.5M | $3.1B | ||
| Q3 24 | $139.0M | $2.9B | ||
| Q2 24 | $159.2M | $2.9B | ||
| Q1 24 | $184.7M | $2.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $26.6M |
| Free Cash FlowOCF − Capex | $-15.8M | $24.4M |
| FCF MarginFCF / Revenue | -84.6% | 83.6% |
| Capex IntensityCapex / Revenue | 0.1% | 7.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $46.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.6M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $-15.8M | $4.9M | ||
| Q1 25 | $-21.0M | $2.3M | ||
| Q4 24 | $-19.9M | $39.0M | ||
| Q3 24 | $-20.7M | $11.9M | ||
| Q2 24 | $-19.5M | $14.6M | ||
| Q1 24 | $-26.0M | $8.2M |
| Q4 25 | — | $24.4M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | $-15.8M | $3.8M | ||
| Q1 25 | $-21.2M | $1.6M | ||
| Q4 24 | $-20.0M | $34.9M | ||
| Q3 24 | $-20.7M | $11.9M | ||
| Q2 24 | $-19.6M | $12.8M | ||
| Q1 24 | $-26.2M | $6.0M |
| Q4 25 | — | 83.6% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | -84.6% | 13.1% | ||
| Q1 25 | -41.6% | 6.0% | ||
| Q4 24 | -52.5% | 133.2% | ||
| Q3 24 | -62.1% | 46.8% | ||
| Q2 24 | -78.2% | 53.1% | ||
| Q1 24 | -63.1% | 25.2% |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.1% | 3.7% | ||
| Q1 25 | 0.2% | 2.8% | ||
| Q4 24 | 0.2% | 15.5% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.4% | 7.3% | ||
| Q1 24 | 0.3% | 9.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | -0.89× | 0.30× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 1.52× | ||
| Q2 24 | — | 2.33× | ||
| Q1 24 | -1.89× | 1.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PCB
Segment breakdown not available.
